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Microchimerism is the presence of cells from one individual in another genetically distinct individual. Pregnancy is the main cause
of natural microchimerism through transplacental bidirectional cell traﬃcking between mother and fetus. The consequences of
pregnancy-related microchimerism are under active investigation. However, many authors have suggested a close relationship
linking fetal microchimerism and the development of autoimmune diseases. It has been more than ten years now since the
demonstration of the presence of a significant high number of fetal microchimeric cells residing in thyroid glands from operated
patients with Graves’ disease. This intrathyroidal fetal microchimerism is an attractive candidate mechanism for the modulation
of Graves’ disease in pregnancy and the postpartum period.
1. Introduction
Microchimerism is defined by the presence of alien cells
within an individual tissue with genetically diﬀerent back-
ground [1]. Microchimeric cells have two possible origins:
natural and artificial. Examples of the former are pregnancy,
miscarriage, and twinning or sexual intercourse, whereas the
most common cases for the later are tissue transplant or
blood transfusion. Pregnancy is the major source of natural
microchimerism.
Contrary to previous expectations, the placental tropho-
blastic physical barrier eﬀect is not a perfect cutoﬀ system.
A certain cell leakage is present between mother and fetus
during gestation, and this transplacental cell traﬃcking is a
two-way process. Fetal cells movement into maternal circu-
lation starts very early during pregnancy. Circulating fetal
cells have been found in maternal blood as soon as the fourth
week of gestation [2], whereas maternal microchimerism has
been detected in a newborn thyroid autopsied at day 2, but
so far has not been reported in thyroid diseases [3]. Earlier
evidences concluded that fetal cells transfer into maternal
circulation was more intense than maternal cells into fetal
blood [4]. However, subsequent investigations estimated that
fetus-to-maternal transfer should be as frequent as maternal-
to-fetus traﬃcking because maternal DNA has been detected
in 40–100% of cord blood samples when polymerase chain
reaction (PCR) techniques were used [5, 6]. The extent of
this phenomenon is universal since fetal cells can be found
in the peripheral blood of almost 100% of women during
pregnancy [7]. Although the level of circulating cells has been
reported to be very low (1 : 500,000 fetal : maternal cells) [8],
such fetal cells can remain after delivery for more than 38
years postpartum [9]. The most plausible explanation for
this long cell persistence is that fetal microchimeric cells can
engraft into maternal bone marrow and provide a renewing
source of fetal cells in maternal blood for decades after de-
livery [10].
So far, only the human leukocyte antigen (HLA) compat-
ibility between mother and fetus has been identified as a
factor influencing the persistence of microchimeric cells.
Microchimerism and chronic graft versus host disease resem-
ble each other. Both diseases share many clinical and
pathological features with autoimmune diseases. Since auto-
immune disease are more frequent in childbearing age
females, it has been hypothesized that fetal microchimerism
maybe involved in their etiology. For a successful pregnancy,
the maternal immune systemmust not overreact to the fetus.
Dramatic changes throughout gestation make possible ma-
ternal tolerance of the fetus and permit fetal cells to move
into maternal circulation and settle in maternal tissues. As a
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Figure 1: Pregnancy is the major source of natural microchim-
erism. Pregnancy related microchimerism results from deficiencies
in the natural placental physical barrier tissue that divide the
maternal circulation from the fetal circulation. As a consequence,
there is mutual and bidirectional maternal and fetal cell traﬃc
during pregnancy. Microchimeric cells enter the circulation and
persist for many years in the host tissues. These cells are tolerated
while acquire specific and diverse biological actions. (Copy of
Figure 5 in [1]).
result, maternal tolerance allows the persistence of fetal mi-
crochimerism (Figure 1).
Intrathyroidal fetal microchimerism has been reported
using diﬀerent techniques. PCR-based analysis identifies Y-
chromosomal and merely demonstrates the presence of male
cells in maternal tissues [11, 12]. Other methodologies, such
as immunohistochemistry, fluorescence in situ hybridization
(FISH) and HLA typing identify location, cellular progeny,
and immunogenic properties of microchimerism in diﬀerent
tissues [13, 14].
2. Effects of Microchimerism
According to cellular characterization, fetal microchimeric
cells could cover a wide spectrum of action. Experimental
data support a variety of important hypotheses concerning
their biological implications. The types of cells crossing the
placenta into the mother include both immune cells and
cytokeratin-positive epithelial cells. Such cells have been
identified as hematopoietic progenitor cells, nucleated ery-
throcytes, trophoblast cells, and leukocytes [15]. Therefore,
microchimeric cells could potentially operate as eﬀectors’
cells or as targets of an immune response. Other possibilities
include reactivity of microchimeric T-cell clones to the non-
shared maternal human leukocyte antigen (HLA) antigens
and presentation of microchimeric peptides by one host cell
to another host cell [16].
We have previously proposed a three-role division for
fetal microchimerism, which covers pathogenic, beneficial,
and neutral microchimerism [1]. The concept of pathogenic
microchimerism initially suggested by Nelson [17], hypoth-
esizes that fetal cells following gestation may lead to a graft
versus host-like reaction in women. Accordingly, maternal
immune response to these foreign cells may support an auto-
immune reaction. It is also plausible the existence of a bene-
ficial microchimerism, where persistent fetal cells may have a
beneficial eﬀect as a new source of progenitor cells potentially
capable to contribute to maternal tissue repair processes. The
third possibility could be neutral microchimerism, where fetal
cells may act as innocent bystanders playing no role in biol-
ogy at all.
In line with our proposedmicrochimeric fetal cells varied
eﬀects, Fugazzola et al. [10] have recently speculated about
three new possible roles of these foreign cells in relation with
cancer, which are cell cancer destruction, tissue repair, and
promotion of cell cancer progression. Apparently, a given
fetal cell could act diﬀerently according to the particular
tissue environment or depending on the type of malignancy.
3. Immune Changes during Pregnancy
For a successful pregnancy, the maternal immune system
must not overreact to the fetus. The mechanisms through
which the immune systems between mother and fetus inter-
act to induce and maintain this immune tolerance are not
fully understood, but several changes have been described.
Trophoblast cells serve both as physical barrier as well as im-
mune modulator by expressing several molecules and secret-
ing specific cytokines. This involves the expression of Fas-
ligand, cytokines, indoleamine 2,3-dioxygenase, immune-
modulating sex steroids, and HLA-G. Fas-ligand is involved
in the removal of maternal T-cell clones that react to fetal
antigens. In animal models, indoleamine 2,3-dioxygenase
catabolizes tryptophan from maternal immune cells in the
placental area, which is essential for a successful pregnancy
in murine models, whereas HLA-G, exclusively expressed
on trophoblast cells, inhibits natural killer cell-mediated
cellular immunity [11].
These changes also include a reduction of T-regulatory
cells activity and aﬀect maternal T-helper (Th) cell dif-
ferentiation. Placental immune modulation promotes sup-
pression of Th1 (cellular), whereas relative enhancement of
Th2 (humoral) immunity occur. Thus placental immune
suppression helps establish fetal microchimerism. Immune
tolerance to fetal implant allows pregnant woman to accept
fetal circulating cells [14]. Consequently, once fetal cell
migrate and take up residence in maternal tissues, they may
survive. This immune suppressionmay remain somemonths
after delivery [18], allowing fetal cells to establish themselves
and to survive the postpartum period [19]. Such dramatic
changes throughout gestation make possible maternal toler-
ance of the fetus and permit fetal cells to move into mater-
nal circulation and settle in maternal tissues. As a result,
maternal tolerance allows the persistence of fetal microchim-
erism.
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This complex modulation of the maternal immune
system by pregnancy is also reflected by the variation of cir-
culating levels of autoantibodies. Furthermore, there is com-
pelling evidences that circulating thyroid autoantibodies are
predictors for the increased risk of pregnancy complications
like miscarriage, breech presentation, or prematurity [20].
Probably thyroid autoimmunity represents a more profound
abnormal immune state, which induces an unstable implant
[21]. For instance, a recent Italian study showed that 37.2%
of thyroid peroxidase (TPO) antibody-positive women had
postpartum thyroiditis, versus 1.7% of the TPO antibody-
negative women. Furthermore, 20% of the TPO antibody-
positive women remained hypothyroid at the end of the
first postpartum year versus 1% of TPO antibody-negative
women [22]. Another classic study described that up to 60%
of reproductive Graves’ disease women reported the onset of
the disease within one year after delivery [23].
At the same time, it has been hypothesized that preg-
nancy-related immune changes have important positive
eﬀects for the fetal immune system. There is evidence sug-
gesting that maternal immune cells instruct fetal cells how
to balance the requirement for self-defense on one hand
and the need for immunologic tolerance on the other. There
is still much to understand about tolerogenic versus immu-
nogenic forms of microchimerism, both of which have been
reported [24].
Taken together, these diﬀerent observations a question
may be raised whether the sequence of events in autoimmu-
nity is at least partly due to alloimmunity rather than auto-
immunity.
4. Pregnancy and Autoimmune Diseases
It is well recognized the highest prevalence of autoimmune
diseases in childbearing-age women than in men. It is also
well known that autoimmune diseases have a profound
influence on pregnancy outcome [19, 25–27]. Hormonal and
genetic factors are probably involved, but a clear explanation
for this type of preponderance is currently lacking. However,
the role of fetal microchimerism as a contributing factor for
the starting or maintenance of the autoimmune reaction in
women is an attractive hypothesis [1].
Fetal cells have been found not just in peripheral blood
but also within a variety of damaged tissues, where the
autoimmune reaction is taking place [11, 28–31]. The pres-
ence of activated immune fetal cells within the maternal tis-
sues may trigger susceptible women to develop autoimmune
disorders. As the placental-induced immune suppression is
vanished, the fetal immune cells may indeed become acti-
vated and initiate the autoimmune reaction [19]. The cause
of this relationship has been based on the degree of HLA dis-
crepancy between host and alien cells which may determine
the status of any potential graft versus host reaction.
On the other hand, it should be emphasized that a
positive eﬀect of pregnancy on autoimmune disease is gen-
erally observed. As previously mentioned, the placenta
induces immune suppression and so lessens autoimmune
activity. Actually, the amelioration of autoimmune clinical
manifestations along gestation is a usual clinical observation.
Experimental data suggest that, despite the relative enhance-
ment of Th2 reaction, both arms of the immune response
(Th1 and Th2) are globally reduced during pregnancy. The
observation is supported by the increase in T-regulatory cells
observed in pregnancy and because autoantibodies greatly
decrease during pregnancy [32].
Assuming that part of microchimeric fetal cells could be
progenitor cells of the fetal immune system, the pathogenic
eﬀect of fetal microchimeric cells in autoimmune diseases
can be perpetuated. These cells could survive in bonemarrow
or move to maternal diﬀerent organs, where they could
proliferate, diﬀerentiate, and activate. The activation of fetal
immature T cells, monocytes, macrophages, and natural
killer cells and the production of inflammatory cytokines and
chemokines are believed to initiate then autoimmune dis-
eases [33, 34]. Alternatively, these cells could be recognized
as partially alloimmune and in consequence give rise to the
autoimmune reaction [10].
Finally, this potential association is also supported by the
observation that, albeit with few exceptions, the resetting to
normal immune status in the postpartum period is usually
coincidental with a clinical exacerbation of many autoim-
mune diseases.
5. Microchimerism and Autoimmune
Thyroid Disease
Several evidences have shown that female subjects with
autoimmune thyroid diseases frequently have microchimeric
fetal cells residing within their thyroid glands [3, 11, 12].
This has been described both in animals [27, 35] and
in humans [11, 12, 14, 36, 37]. Whether the presence
of fetal cells increases maternal thyroiditis or a previous
episode of thyroiditis increases the recruitment of these fetal
cells remains unknown. A number of studies revealed this
association demonstrating that the prevalence of male cells
is higher in women with autoimmune thyroid diseases who
previously had given birth to a son than in women without
autoimmune thyroid diseases who previously had given
birth to a son [10, 14]. These results generate the attractive
hypothesis of a causal relationship between microchimerism
and autoimmune thyroid diseases.
Davies’ laboratory has extensively investigated the influ-
ence of pregnancy in autoimmune thyroid diseases, includ-
ing the relationship between fetal microchimerism and
autoimmune thyroid diseases [27, 35]. The group initially
found that experimental autoimmune thyroiditis in mice
enhanced the accumulation of intrathyroidal fetal cells
during pregnancy [35]. The murine model of experimental
autoimmune thyroiditis was established in female mice
using murine thyroglobulin (Tg) as antigen. Tg-treated mice
developed a florid lymphocytic infiltration by 4–6 weeks after
immunization [27]. In addition, the results showed that there
were no significant diﬀerences in thyroid function between
nonimmunized and Tg-immunized pregnant mice.
Davies’ group, going forward in the study of fetal
microchimerism as a cause involved in the development
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of autoimmune thyroid disease, used their experimen-
tal autoimmune thyroiditis model using sex-determining
region Y (SRY) gene as the marker of presence of male
microchimeric cells within maternal thyroids. The results
demonstrated the presence of fetal cells in 46% of Tg-
immunized pregnant mice, whereas few male fetal cells were
detected in only 20% of controls or nonimmunized pregnant
mice. Subsequent studies of cell characterization revealed
the immune origin of the cells that accumulate within the
thyroid of mice with experimental autoimmune thyroiditis
during pregnancy and early postpartum [35]. These fetal
cells were identified as regulatory and cytotoxic CD4+
(in a significant proportion), CD11c+, and weakly CD8+,
but not from B220/CD45R+, CD11b+, or Sca-1+, which
indicates that intra-thyroidal fetal cells included T-cell and
dendritic cell lineage. This was accompanied by high titers of
antibodies to Tg. Furthermore, mice postpartum followup
revealed that intra-thyroidal fetal cells were most easily
seen in experimental autoimmune thyroiditis animals during
pregnancy, whereas the presence of these cells decreased in
the postpartum period. So, a fetal cell-induced modulation
during pregnancy and postpartum was highly feasible.
As aforementioned, several clinical studies have found
male cells in thyroid samples of women previously diagnosed
of Hashimoto’s thyroiditis [12–14, 37]. The presence of
alien cells in autoimmune involved thyroids ranged between
38 and 83%. This wide spectrum of percentages probably
reflects the discrepancies in study design. Interestingly, the
percentage diﬀerences between the Hashimoto’s thyroiditis
and control groups in individual studies are constant.
Although the presence of fetal microchimerism was not
identified in normal thyroids or patients with nodular goiters
by all authors [12, 13], nowadays it is considered that
microchimeric cells are present in normal glands and around
20% of follicular adenomas [10]. A recent Italian report
has revealed fetal microchimeric cells in normal maternal
thyroid tissue [38]. The authors explain the discrepancy
due to the diﬀerent origin of normal samples, from the
normal tissue contralateral, to a neoplastic lesion. This
finding further supports the idea that, in the presence of
a neoplastic process, microchimeric cells could migrate to
the thyroid and participate in the repair process [38]. All
in all, these results indicate a higher number of fetal micro-
chimeric cells in autoimmune thyroid diseases than in nor-
mal thyroids or benign proliferative disorders [11, 14, 19, 37].
Therefore taken together, these findings strongly support a
possible pathogenic role for fetal microchimeric cells in the
development autoimmune thyroid disease. However, there
is still an important missing link that is the presence of
maternal microchimerism in male patients with Graves’
disease, which has been poorly studied.
6. Fetal Microchimerism and Graves’ Disease
6.1. Graves’ Disease in Pregnancy. Pregnancy-related factors
have a strong influence in Graves’ disease [25]. Normally,
the clinical course of Graves’ disease improves as pregnan-
cy progresses, paralleling the reduction in serum TSH
receptor (TSH-R) autoantibodies level. The reflection of
this clinical improvement could be not only the quantity
of serum anti-body concentration but also the quality (or
the biological action) of these antibodies. Some authors
have hypothesized that the equilibrium between TSH-R
antibodies blocking and stimulating activities may shift
in favor of blocking antibodies [39], though not all the
experts share this opinion [40]. In any event, a fluctuant
Graves’ disease clinical evolution is a common finding during
pregnancy with exacerbation during approximately the first
three months and improvement in the last trimester [41].
In the postpartum period as the pregnancy-associated
immune-privileged state disappears, a relapse, exacerbation,
or new onset of Graves’ disease may occur. This outbreak
normally happens between 4–12 months after delivery [42].
In fact, epidemiological studies show that around 60% of
childbearing age women develop Graves’ disease during the
first year after delivery [29, 43], whereas the frequency of
relapses varies from 30% to 70% of cases [44]. Likewise, an
increased risk of developing Graves’ disease after pregnancy
may be greater in older patients (>35 years), and this risk lasts
for several years after delivery [21, 45].
6.2. Experimental Evidence. It was also Davies’ group who
in 2002 first demonstrated that intrathyroidal fetal micro-
chimerism was common and profound in female patients
with Graves’ disease [11]. Renne´ et al. confirmed these
findings two years later [14]. Since then, more information
has arisen in the scientific arena [10].
Davies’ group research was conducted in a sample of 27
thyroid glands from patients with a past medical history of
Graves’ disease [11]. The investigators analyze the presence
of male-specific SRY gene in maternal thyroid glands by
ELISA-PCR technique for the detection of DNA. This was
a two-step designed study. Initially, male cell assay was
applied to screen for circulating peripheral blood fetal
micro-chimerism in 20 females and lastly in stored thyroid
tissue. The preliminary results showed that none of 16
never-pregnant females had male cells detected. However, in
previous pregnant women, male cells were easily detected in
28.6% of blood samples. Furthermore, 47% of female Graves’
blood specimens contained significant male cells. These
results were similar to prior reports indicating that periph-
eral blood fetal microchimerism is a common finding in
childbearing-age women.
A subsequent analysis was focused on thyroid samples
from females previously diagnosed of Graves’ and in a group
of thyroid adenomas as control. The storage of the thyroid
samples had been diversed. Twenty glands had been prepared
in paraﬃn blocks, whereas the remaining seven were frozen.
Interestingly, SRY gene was found in only 20% of paraﬃn
embedded tissues, while 86% of the frozen samples were
positive for the Y chromosome gene. In the former group,
the ratio of male to female cells ranges from 14 to 295 by
105, with a median of 37/105 male/female cells. SRY gene
was searched in 10 thyroid adenoma specimens (6 in paraﬃn
and 4 frozen). None of the 6 paraﬃn-embedded thyroid ad-
enoma was positive for the SRY gene analysis, whereas 1 out
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Table 1: Summary of the main experimental and clinical findings of Graves’ disease and microchimerism.
Thyroid tissue origin Storage N Gene and technique Presence of microchimeric cells (%) Reference
Graves’ disease
Paraﬃn-embedded 20 SRY gene by ELISA-PCR 20% Ando et al. [11]
Frozen 7 SRY gene by ELISA-PCR 86% Ando et al. [11]
Paraﬃn-embedded 15 X and Y chromosomes by FISH 40% Renne´ et al. [14]
Thyroid adenoma
Paraﬃn-embedded 6 SRY gene by ELISA-PCR 0% Ando et al. [11]
Frozen 4 SRY gene by ELISA-PCR 25% Ando et al. [11]
Paraﬃn-embedded 9 X and Y chromosomes by FISH 22% Renne´ et al. [14]
Hashimoto’s thyroiditis Paraﬃn-embedded 25 X and Y chromosomes by FISH 60% Renne´ et al. [14]
SRY: sex-determining region Y; PCR: polymerase chain reaction; FISH: fluorescence in situ hybridization.
of 4 frozen samples with thyroid nodules showed male cells.
Authors speculate that the greater detection of the SRY gene
in frozen female thyroid tissues was probably due to DNA
fragmentation in the paraﬃn-derived samples. Unexpect-
edly, many of the patients with male cell-positive thyroids
had no history of earlier male pregnancies at the time of sur-
gery. However, as the authors stated in the discussion, this did
not necessarily exclude the possibility of undetected first
trimester pregnancies because it has been demonstrated that
fetal microchimerism can be established in the first month of
pregnancy [11, 46].
Renne´ et al. study compared three entities: Graves’
disease, Hashimoto’s thyroiditis, and nodular or diﬀuse
follicular adenomas from women whose childbirth history
was positive for sons [14]. These investigators screened by
fluorescence in situ hybridization for X chromosome and
Y chromosome specific staining from paraﬃn-embedded
thyroid specimen taken at surgery. The results showed that 23
out of 49 thyroids (47%) were positive for Y-chromosome-
specific staining. These authors found no Y-chromosomes-
positive thyrocytes. The proportion of Y-chromosome-
positive thyroid section was highest in Hashimoto’s thy-
roiditis (15/25; 60%), lower in Graves’ disease (6/15; 40%),
and infrequent in follicular adenomas (2/9; 22%) [14].
The results indicate a higher degree of microchimerism in
autoimmune thyroid disease than in benign proliferative
disorder. The results were consistent with previous reports
also showing that microchimeric cells are found in more
subjects with autoimmune thyroid diseases than in any other
thyroid diseases [11, 13].
A summary of these findings is presented in Table 1.
7. Controversial Studies about the Relationship
between Microchimerism and AITD
Those dissenting from the appraisal of the relation between
autoimmune thyroid disease and microchimerism mainly
base on data from epidemiological studies. An Australian
study over a large community-based female population
(1,045 participants) showed no association between parity
and presence of thyroid autoantibodies or thyroid dys-
function. Hence, the authors suggested a lesser role of
fetal microchimerism in autoimmune thyroid diseases [47].
A year later, a Danish group also investigated the association
between the presence of circulating thyroid autoantibodies
and previous pregnancy, parity, and the use of estrogens in
an even larger population cohort of 3,712 women. These
authors reinforce the Australian conclusion, as they also did
not find any association between thyroid antibodies and
pregnancy. No association was observed between hormonal
replacement therapy and serum TPO antibodies levels either.
In line with the Australian authors, the Danish investigators
concluded that there was no association between previous
pregnancy and serum thyroid Abs level, which argues, in
their opinion, against the role of microchimerism as a trigger
factor of thyroid autoimmunity [48]. These two studies seem
to indicate that the risk of having TPO antibodies or Tg
antibodies was similar in nulliparous women compared with
women with one or more previous pregnancies. However,
recently in 2011, an American study was published with a
confronting conclusion [49]. The authors analyze the rela-
tionship between TPO antibodies and increasing parity in a
population of 17,298 women, larger than the two previous
samples. The authors analyze the relationship of serum
TPO antibody levels and increasing parity. Despite that
the incidence of abnormally elevated TPO antibody levels
increased with advancing parity, this trend was not signifi-
cant after adjustment for maternal characteristics. However
at higher TPO antibody levels, a significant relationship
with advancing parity persisted after adjustments. Therefore,
it was concluded that advancing parity is associated with
an increased risk for high serum concentrations of TPO
antibodies, suggesting that fetal microchimerism may play
a role in development of autoimmune thyroid disorders
[49]. The two main results from this large American study
could help to explain why Australian and Danish authors
could not find any relationship between parity and presence
of TPO antibody levels. Nevertheless, it remains to be
demonstrated that the establishment of microchimeric cells
openly influences the natural history of autoimmune thyroid
diseases.
8. Conclusions
Currently, there is a large body of evidence showing that
maternal thyroid gland is a significant organ where a variety
of fetal cells settle and persist for decades. These foreign
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immune cells may be activated after delivery once placental
immune suppression is over. This remains an attractive
hypothesis for the postpartum increase of prevalence of
Graves’ disease.
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